Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2025 Earnings Call Transcript August 5, 2025Madrigal Pharmaceuticals, Inc. beats earnings expectations.
Madrigal Pharmaceuticals Inc. (MDGL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paulson & Co John Paulson | 2,089,523 | $632,373,241 | -1% | 31.44% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,976,018 | $598,022,088 | +1% | 5.8% |
| 3. | VenBio Select Advisor Kurt Von Emster | 1,875,000 | $567,450,000 | -8% | 9.94% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 376,163 | $113,841,970 | +97% | 0.19% |
| 5. | Hood River Capital Management David Swank | 244,738 | $74,067,508 | +1% | 1.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $229.86 | 3,960 | $910,264.21 | 1,793,403 | 2023-12-14 | Filing | |
| $229.86 | 316 | $72,637.25 | 185,979 | 2023-12-14 | Filing | |
| $228.79 | 2,204 | $504,251.62 | 1,789,443 | 2023-12-14 | Filing | |
| $228.79 | 176 | $40,266.92 | 185,663 | 2023-12-14 | Filing | |
| $227.86 | 11,602 | $2,643,596.91 | 1,787,239 | 2023-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $368.56 | 896 | $330,225.91 | 2,627 | 2025-08-15 | Filing | |
| $367.63 | 1,104 | $405,864.73 | 3,523 | 2025-08-15 | Filing | |
| $366.14 | 600 | $219,682.98 | 4,627 | 2025-08-15 | Filing | |
| $365.33 | 2,567 | $937,792.87 | 5,227 | 2025-08-15 | Filing | |
| $364.24 | 2,516 | $916,427.59 | 7,794 | 2025-08-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,191,753 | $663,279,292 | 0.33% | |
| 2. | 1,993,687 | $603,369,434 | 8.59% | |
| 3. | 1,877,281 | $568,140,321 | 0.01% | |
| 4. | 1,438,724 | $435,415,581 | 0.01% | |
| 5. | 690,715 | $209,037,988 | 0.01% |
News See All
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH.
Madrigal (MDGL) Secures $500M to Fuel MASH Pipeline Expansion
Madrigal Pharmaceuticals (NASDAQ:MDGL) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
10 Most Undervalued Healthcare Stocks to Buy According to Analysts
The CEO of Pivotal Advisors, Tiffany McGhee, spoke on CNBC on June 27 on what investors should do in light of the current state of the market.
JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential
Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Billionaire Nicholas J. Pritzker's 8 Stocks with Huge Upside Potential
Nicholas J. Pritzker is the chairman and co-founder of Tao Capital Partners, a San Francisco-based venture capital firm established in 2013.
Billionaire Hedge Funds
